Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY-1: ALPN-303 in Healthy Volunteers
NCT05034484Phase 1Completed
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of povetacicept in systemic lupus erythematosus (SLE), IgA nephropathy (IgAN) and autoimmune cytopenia (4 arms), sponsored by Alpine Immune Sciences, Inc. Primary endpoint: Treatment-emergent Adverse Events. Started Nov 2021; status: completed.
02
Drugs
povetacicept
03
Conditions
systemic lupus erythematosus (SLE)IgA nephropathy (IgAN)autoimmune cytopenia
Beyond the preview
Go deeper on NCT05034484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034484.